MARKET

DGNOF

DGNOF

Diagnos Inc
OTCMQB
0.308
-0.006
-2.04%
Closed 15:55 09/10 EDT
OPEN
0.311
PREV CLOSE
0.314
HIGH
0.319
LOW
0.308
VOLUME
15.50K
TURNOVER
4.82K
52 WEEK HIGH
0.360
52 WEEK LOW
0.026
MARKET CAP
37.24M
P/E (TTM)
-10.1551
1D
5D
1M
3M
1Y
5Y
1D
DIAGNOS Receives Saudi FDA Medical Device License for CARA System, Bringing AI-Assisted Retinal Image Analysis to Saudi Arabia
Barchart · 08/13 13:21
DIAGNOS Receives Health Canada Medical Device Licence for CARA System, Bringing AI-Assisted Retinal Image Analysis to Canadian Optometrists
Barchart · 07/27 14:20
DIAGNOS to Extend the Exercise Period of Stock Warrants
Barchart · 07/07 11:38
DIAGNOS Announces Shares for Debt Settlement
Barchart · 06/18 11:00
Emerging Growth Research Releases Flash Report on DIAGNOS, Highlighting Regulatory Catalysts and Commercialization Potential for CARA AI Platform
Barchart · 06/05 09:00
DIAGNOS Successfully Completes the Renewal of US-FDA Medical Device Establishment Registration
Barchart · 04/01 10:50
DIAGNOS and ÉTS Announce $1M+ Federal Investment to Propel Next-Generation Retinal AI Innovation
Barchart · 02/04 08:30
DIAGNOS Announces the Engagement of IBN
Barchart · 01/15 14:30
More
About DGNOF
Diagnos Inc. is a Canadian company, which is engaged in the early detection of critical eye-related health problems using advanced technology based on Artificial Intelligence (AI). It markets Computer Assisted Retinal Analysis (CARA), a software platform which assists health specialists in the detection of certain retinopathy pathologies through the computerized analysis of retina images. CARA is an in-house-hosted Web-based application that integrates fundus cameras with an image processing engine over a secure Internet connection. The CARA suite of applications allows an eye care specialist to more clearly visualize both normal retinal landmarks (optic nerve, vascular system, macula, fovea), and pathological changes (exudates, haemorrhages, micro-aneurisms, neo-vascularization). CARA is indicated for use by healthcare professionals in an adult general population in the context of a general eye-health exam.

Webull offers Diagnos Inc stock information, including OTCMQB: DGNOF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, DGNOF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading DGNOF stock methods without spending real money on the virtual paper trading platform.